Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 High Yield Dividend Stocks with Sustainable Payouts.
On January 27, Citi analyst Geoff Meacham raised his price objective on Bristol-Myers Squibb Company (NYSE:BMY) to $60 from $53. The analyst maintained a Neutral rating and mentioned that the change came as part of a broader Q4 preview for the biopharma sector. Citi adjusted targets across the group, with Meacham noting that estimates that are “beatable” and lower policy risk could create a more favorable setup for the sector in 2026.
Separately, Bristol Myers recently announced a partnership with Microsoft focused on earlier detection of lung cancer. Under the agreement, the company will use Microsoft’s AI-enabled radiology platform, which deploys US Food and Drug Administration-cleared algorithms through the Precision Imaging Network. The system analyzes X-ray and CT scans to help identify lung disease and is already in use at hospitals across the United States. Bristol Myers said the tools could help clinicians find hard-to-detect lung nodules and identify some patients at earlier stages.
The company said a key goal of the partnership is to expand access to early detection in medically underserved areas. That includes rural hospitals and community clinics across the US.
While the announcement itself is relatively small, it highlights the practical value AI can bring to clinical care. If the effort delivers results, it would not be surprising to see Bristol Myers expand the approach to other disease areas.
Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with serious diseases, including cancer, blood disorders, immune conditions, cardiovascular disease, and neurological disorders.
While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 13 Best February Dividend Stocks To Buy and 12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds
Disclosure: None.
